It is the function of this office to collect, abstract, code, update, process, analyze and present the data submitted by member institutions. Additionally, the GOG Statistical Office coordinates and manages the GOG Quality Assurance Audit program, performs follow-up quality control, plays a major role in the design, formatting and randomization of all new protocols, implements interim and final Protocol Chair Reviews, and is the focal point for the preparation of all GOG abstracts and manuscripts for publication. Our principal objective is to manage patient data in an efficient and accurate manner, resulting in timely analyses, logical and appropriate interpretation of expansion and application of the GOG Management Information System to keep pace with the corresponding growth of GOG. Similarly, expanding the intrinsic involvement of protocol chairs in the review and analyses of their studies is essential in maintaining the desired quality of data required by GOG standards. The achievement of these goals will have a direct bearing upon the future management of patients with gynecologic malignancies. The methodology involved consists of: (a) Involvement of GOG Statistical Office in all phases of study design, conduct, data management, quality control and interpretation as mandated by GOG Protocol Procedures Manual; (b)Responsibility for modality reviews of pathology, radiotherapy and gynecologic management; (c) Early determination and implementation of protocol-specific abstraction on all studies; (d) Continued expanded use of computer evaluation sheets (EVL's) which provide a viable vehicle to foster interaction among study chairman, data abstractor, and statistician; this methodology enables each protocol to be thoroughly reviewed twice- yearly in order to resolve questions and incorporate comments or suggestions into the patient data; (e) Responsibility for the conduct and reporting of all GOG Quality Assurance Audits; (f) Coordination, monitoring, preparation, and timely submission of all GOG publications.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA037517-17
Application #
6375709
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1984-07-01
Project End
2002-03-31
Budget Start
2001-04-01
Budget End
2002-03-31
Support Year
17
Fiscal Year
2001
Total Cost
$4,467,226
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Horowitz, Neil S; Larry Maxwell, G; Miller, Austin et al. (2018) Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol 148:49-55
Bishop, Erin A; Java, James J; Moore, Kathleen N et al. (2018) Surgical outcomes among elderly women with endometrial cancerĀ treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol 218:109.e1-109.e11
Valicenti, Richard K; Pugh, Stephanie L; Trabulsi, Edouard J et al. (2018) First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. Int J Radiat Oncol Biol Phys 100:695-701
Aghajanian, Carol; Filiaci, Virginia; Dizon, Don S et al. (2018) A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. Gynecol Oncol 150:274-281
Monk, Bradley J; Kauderer, James T; Moxley, Katherine M et al. (2018) A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol 151:422-427
Hensley, Martee L; Enserro, Danielle; Hatcher, Helen et al. (2018) Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol :JCO1800454
Felix, A S; Brasky, T M; Cohn, D E et al. (2018) Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Int J Cancer 142:1102-1115
Matulonis, Ursula A; Sill, Michael W; Makker, Vicky et al. (2018) A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol :
Boardman, Cecelia H; Brady, William E; Dizon, Don S et al. (2018) A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic On Gynecol Oncol 151:202-207
Felix, Ashley S; Cohn, David E; Brasky, Theodore M et al. (2018) Receipt of adjuvant endometrial cancer treatment according to race: anĀ NRG Oncology/Gynecologic Oncology Group 210 Study. Am J Obstet Gynecol 219:459.e1-459.e11

Showing the most recent 10 out of 484 publications